DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Information source: Janssen Research & Development, LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Myeloma

Intervention: Siltuximab11 mg/kg (Drug); Siltuximab 8.3 mg/kg or 11 mg/kg (Drug); Velcade (bortezomib) (Drug); Velcade (bortezomib) (Drug); Melphalan (Drug); Melphalan (Drug); Prednisone (Drug); Prednisone (Drug); Velcade (bortezomib) (Drug); Melphalan (Drug); Prednisone (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Janssen Research & Development, LLC

Official(s) and/or principal investigator(s):
Janssen Research & Development L.L.C Clinical Trial, Study Director, Affiliation: Janssen Research & Development L.L.C

Summary

The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple myeloma (a type of cancer that affects the blood and bone marrow).

Clinical Details

Official title: A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria

Secondary outcome:

Percentage of Participants Who Achieved Overall Response ie, Complete Response (CR) or Partial Response (PR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria

Percentage of Participants Who Achieved Stringent Complete Response (sCR) - International Myeloma Working Group (IMWG) Criteria

Progression-Free Survival (PFS)

1-year Progression-Free Survival (PFS) Rate

Duration of Response (DOR)

1-year Survival Rate

Overall Survival

Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)

Detailed description: The study will be conducted in 2 parts (Part 1 and Part 2) and will consist of screening period up to 2 weeks; treatment period; maintenance period (CNTO 328 hereafter referred to as siltuximab) for a maximum of 18 months and follow up period until the study ends. Part 1 is an open-label (all people know the identity of the intervention), single group safety lead-in part to evaluate the safety of siltuximab. Approximately 12 patients will be treated with siltuximab in combination with VMP. If the safety profile of the combination is acceptable, the study will proceed to Part 2. Part 2 is a randomized (the study medication is assigned by chance), open-label, 2-arm (Arm A: siltuximab + VMP; Arm B: VMP alone) study. Approximately 104 patients will be equally randomized, followed by a maintenance period with siltuximab in particiants in Arm A who achieve a partial response (PR) or better. Particiants in both parts of the study will be treated up to a maximum of nine 6-week cycles provided there is no evidence of disease progression, unacceptable toxicity, or withdrawal from treatment. Study medication will be continued for at least 2 additional cycles after confirmation of complete response, and preferably for the full 9 cycles of the treatment period. Participants who will be receiving maintenance treatment after the 12-month effectiveness analysis may continue to receive treatment with siltuximab only after careful consideration by the treating physician and on evidence of clinical benefit and in the absence of unwarranted toxicities. Safety assessments will include evaluation of adverse events, clinical laboratory tests, eastern cooperative oncology group performance status, electrocardiogram, vital signs, and physical examination which will be monitored throughout the study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Confirmed diagnosis of previously untreated multiple myeloma and not a candidate for

high dose chemotherapy with stem cell transplantation

- Eastern cooperative oncology group performance status score of less than or equal to

2

- Measurable secretory disease, defined as either serum monoclonal paraprotein greater

than or equal to 1 g/dL or urine monoclonal protein greater than 200 mg/24 hours

- Adequate laboratory results that will be confirmed by a study physician

- Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

- Diagnosed with primary amyloidosis, asymptomatic or smoldering multiple myeloma or

monoclonal gammopathy of undetermined significance

- Diagnosed with Waldenstrom's disease, or other conditions in which IgM M-protein is

present in the absence of a clonal plasma cell infiltration with lytic bone lesions

- Received prior or current systemic therapy or stem cell transplantation for multiple

myeloma

- Peripheral neuropathy or neuropathic pain (Grade 2 or higher)

- Received radiation therapy, plasmapheresis or surgery within 14 days

- Transplanted solid organ, with the exception of a corneal transplant

- Serious concurrent illness or history of uncontrolled heart disease

Locations and Contacts

Adelaide, Australia

Melbourne, Australia

Bordeaux Cedex, France

Montpellier, France

Strasbourg, France

Ahmedabad, India

Calicut, India

Hyderabad N/A, India

Jaipur, India

Mumbai, India

Afula, Israel

Haifa, Israel

Jerusalem, Israel

Petah Tikva, Israel

Ramat-Gan, Israel

Seoul, Korea, Republic of

Bialystok, Poland

Chorzów, Poland

Gdynia, Poland

Lodz, Poland

Wroclaw, Poland

Baia Mare, Romania

Brasov, Romania

Iasi, Romania

Arkhangelsk, Russian Federation

Moscow N/A, Russian Federation

Nizhni Novgorod, Russian Federation

St. Petersburg, Russian Federation

Singapore, Singapore

Barcelona, Spain

Madrid, Spain

Murcia N/A, Spain

Salamanca, Spain

Boston, Massachusetts, United States

Chapel Hill, North Carolina, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Additional Information

Starting date: June 2009
Last updated: November 17, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017